Online inquiry

IVTScrip™ mRNA-Anti-MSTN, ACE-031(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ1541MR)

This product GTTS-WQ1541MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets MSTN gene. The antibody can be applied in Duchenne muscular dystrophy (DMD) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_005259.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2660
UniProt ID O14793
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-MSTN, ACE-031(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ1541MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ9676MR IVTScrip™ mRNA-Anti-CD19&CD3E, JNJ-64052781(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA JNJ-64052781
GTTS-WQ4192MR IVTScrip™ mRNA-Anti-IL2RA, BIIB019(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA BIIB019
GTTS-WQ11464MR IVTScrip™ mRNA-Anti-ERBB3, MEHD7945A(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MEHD7945A
GTTS-WQ7809MR IVTScrip™ mRNA-Anti-env, GS-HIV(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA GS-HIV
GTTS-WQ2066MR IVTScrip™ mRNA-Anti-Canlupfam PDCD1, AH-PD1(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA AH-PD1
GTTS-WQ10275MR IVTScrip™ mRNA-Anti-C5, LFG 316(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA LFG 316
GTTS-WQ6806MR IVTScrip™ mRNA-Anti-STEAP1, DSTP-3086S(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA DSTP-3086S
GTTS-WQ5754MR IVTScrip™ mRNA-Anti-EGFR, CetuxiMab-GEX(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA CetuxiMab-GEX
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW